In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Financing Innovation Strategy

Snapshot: August Highlights

  • Data

Executive Summary

A selection of articles you might have missed from August 2022, including a discussion on fake medicines and what's needed to tackle their existence, the die down of SPAC deals and how device-activated drugs may unlock new therapeutic avenues.

You may also be interested in...



Execs On The Move, January 2023: Spun-Off GE Healthcare Names Board, Officers

An interactive view of medtech executive changes from the month of January 2023, including GE Healthcare's new leadership as a standalone company.

Axogen, Dario Health, Biobeat, Immunexpress All Weigh In On 2022 And What Will Succeed In 2023

Medtech Insight was invited to ask questions at a roundtable event organized by Russo Partners to review the major medtech industry trends of 2022 and what to expect in 2023.

Snapshot: January Highlights

A selection of articles you may have missed from January 2023, covering the FDA's approach to gene therapies and their long-term implications, the rise (and possible fall) of Chinese companies' efforts in drug development and the ongoing consideration of the 'E' in ESG.

Table

View full table

Topics

Tags:
Financing Innovation Strategy
Latest Headlines

Slew Of Challenges Calls For Revised Biopharma Playbook

Roivant Is Striving Towards New Standards Of Care

The Mandate To Make A Digital Difference

Snapshot: January Highlights

See All
UsernamePublicRestriction

Register

IV146682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By